SLAM/CD150 Antibody [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # AF4330F
Conjugate
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
Western Blot, Flow Cytometry, CyTOF-ready
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Polyclonal Sheep IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant mouse SLAM/CD150
Thr25-Pro242
Accession # Q9QUM4
Thr25-Pro242
Accession # Q9QUM4
Specificity
Detects mouse SLAM/CD150 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human SLAM is observed.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Applications for SLAM/CD150 Antibody [FITC]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SLAM/CD150
Long Name
Signaling Lymphocytic Activation Molecule
Alternate Names
CD150, IPO-3, SLAMF1
Gene Symbol
SLAMF1
Additional SLAM/CD150 Products
Product Documents for SLAM/CD150 Antibody [FITC]
Product Specific Notices for SLAM/CD150 Antibody [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...